Literature DB >> 22974958

Extremely marginal liver grafts from deceased donors have outcome similar to ideal grafts.

N Goldaracena1, E Quiñonez, P Méndez, M Anders, F Orozco Ganem, R Mastai, L McCormack.   

Abstract

BACKGROUND: Although there is a worldwide need to expand the donor pool, many cadaveric marginal livers are usually discarded for transplantation. Herein, we report the outcome of a series of patients receiving marginal grafts.
METHODS: We analyzed all patients who underwent liver transplantation in our unit from August 2006 to March 2011 (n = 125) with the use of a prospectively collected database. Patients with ≥3 of donor (prolonged hypotensive episodes, donor age >55 years, high vasopressor drug requirement, hypernatremia, prolonged intensive care unit stay, elevated transaminases) and graft-related (cold ischemia >12 hours, warm ischemia time >40 minutes and steatosis >30%) extended criteria were defined as extremely marginal liver grafts (EMLG). The outcomes of patients receiving EMLG were compared with the recipients of grafts without any marginal criteria (ideal grafts).
RESULTS: The EMLG group (n = 36) showed higher operative transfusion requirement (66.6% vs 55.6%) as well as 30-day (11.1% vs 55%) and 1-year (22.2% vs 5.5%) mortality rates, compared with the ideal grafts group (n = 18) but without a significant difference. Other variables, such as major complications, postoperative hemodialysis, ICU and hospital stay, and 1-year survival also were not significantly different.
CONCLUSIONS: The liver pool can be safely expanded using EMLG from deceased donors for liver transplantation. These usually discarded liver grafts showed similar early and long-term outcomes compared with ideal organs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22974958     DOI: 10.1016/j.transproceed.2012.07.113

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Resolution of donor non-alcoholic fatty liver disease following liver transplantation.

Authors:  Andrew D Posner; Samuel T Sultan; Norann A Zaghloul; William S Twaddell; David A Bruno; Steven I Hanish; William R Hutson; Laci Hebert; Rolf N Barth; John C LaMattina
Journal:  Clin Transplant       Date:  2017-07-13       Impact factor: 2.863

2.  Successful adult-to-adult living donor liver transplantation using liver allograft after the resection of hemangioma: A suggestive case for a further expansion of living donor pool.

Authors:  Yasuharu Onishi; Hideya Kamei; Hisashi Imai; Nobuhiko Kurata; Tomohide Hori; Yasuhiro Ogura
Journal:  Int J Surg Case Rep       Date:  2015-10-08

3.  Transplantation of Deceased Donor Livers With Elevated Levels of Serum Transaminases at Shiraz Transplant Center.

Authors:  Nasir Fakhar; Saman Nikeghbalian; Kourosh Kazemi; Ali Reza Shamsayeefar; Siavash Gholami; Amir Kasraianfard; Seyed Ali Malek-Hosseini
Journal:  Hepat Mon       Date:  2016-10-08       Impact factor: 0.660

4.  The Differential Influence of Cold Ischemia Time on Outcome After Liver Transplantation for Different Indications-Who Is at Risk? A Collaborative Transplant Study Report.

Authors:  Vladimir J Lozanovski; Bernd Döhler; Karl Heinz Weiss; Arianeb Mehrabi; Caner Süsal
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

5.  Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases.

Authors:  Guoqiang Li; Xiaoxin Mu; Xinli Huang; Xiaofeng Qian; Jianjie Qin; Zhongming Tan; Wenjie Zhang; Xiaoliang Xu; Shanbai Tan; Zhijun Zhu; Wei Li; Xuan Wang; Xuehao Wang; Beicheng Sun
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

6.  The Graz Liver Allocation Strategy-Impact of Extended Criteria Grafts on Outcome Considering Immunological Aspects.

Authors:  Judith Kahn; Gudrun Pregartner; Alexander Avian; Daniela Kniepeiss; Helmut Müller; Peter Schemmer
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.